Indications › Chronic kidney disease
GLP‑1 drugs in chronic kidney disease
Which incretin agents are being studied in chronic kidney disease, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.
- Trials on file
- 21
- Active
- 11
- Results scheduled
- 6
- Molecules studied
- 7
- Sponsors
- 13
FDA-approved for chronic kidney disease: semaglutide. Approval wording is on each drug page, quoted from the label.
1 of the molecules tracked here is FDA-approved for chronic kidney disease, so the trials below are asking further questions rather than establishing whether the class works at all. 13 of the 21 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 8 still in early phases. 13 distinct sponsors are involved, 10 of the trials run commercially and the rest by universities and hospitals.
Molecules studied in this indication
dulaglutide · exenatide · orforglipron · retatrutide · semaglutide in this indication · survodutide · tirzepatide
Results due in this indication
Trials on file
All 21 incretin trials recorded in this indication, active first.